Somaxon Pharmaceuticals — Investor Presentation (January 2008)
33 slides from Somaxon Pharmaceuticals's investor presentation, Jan 7, 2008
Slide 1: Specialty Pharmaceuticals for Psychiatry & Neurology
Specialty Pharmaceuticals for Psychiatry & Neurology NASDAQ: SOMX
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about our business, including results of our clinical trials, potential indications for our product candidates, development timelines, future financial results and events that have not yet occurred. Pharmaceutical devel
Slide 3: Focused on Psychiatric and Neurologic Disorders
Focused on Psychiatric and Neurologic Disorders SILENOR(tm): Product candidate for treatment of insomnia Completed four successful Phase 3 clinical trials Differentiated product profile creates significant market potential Planning NDA filing in Q1 2008 Conducting ongoing discussions regarding strat
Slide 4: Insomnia: An Attractive Market
2002 2003 2004 2005 2006 2007 Ambien 36 40 43 47 56 62 Insomnia: An Attractive Market Total Rx Millions Total Prescriptions Source: Wolters Kluwer Health *Data through 11/07, year-end projection CAGR 11.4% *
Slide 5: Frequency of Insomnia is High
Frequency of Insomnia is High Every Night A Few Nights per Week A Few Nights per Month Rarely Never East 0.33 0.21 0.25 0.19 0.02 National Sleep Foundation. 2005. 54% 70 million adults suffer from insomnia 25 million with chronic and/or severe insomnia % of Respondents
Slide 6: Market Opportunity
Market Opportunity Only ~20% take an Rx sleep aid 30% don't take prescribed sleep Rx due to fear of dependence 26% don't take prescribed sleep Rx due to fear of side effects Source: Mintel Premier 2006; Somaxon market research 34% of diagnosed patients not on an Rx sleep drug feel that sleep drugs h
Slide 7: Common Insomnia Complaints
Common Insomnia Complaints Source: Sleep in America Poll 2005 Difficulty falling asleep Wake feeling unrefreshed 22% 22% 32% 38% Waking frequently during the night Waking too early Sleep Maintenance 32% 22%
Slide 8: Patients Want Better Options
Patients Want Better Options Source: Somaxon market research "How well would you say your insomnia/sleep problem is controlled?" Somewhat controlled 49% Completely/Well controlled 12% Poorly/Not at all controlled 39% 70% of insomnia sufferers sleep <6 hours/night
Slide 9: Limitations of Current Insomnia Treatments
Limitations of Current Insomnia Treatments Commonly cited reasons for dissatisfaction include: Fear of dependence Risk of memory impairment, confusion, sedation, falls Next day hangover and impaired daytime functioning Anticholinergic effects Development of tolerance Inability to sleep through the n
Slide 10: Evolution of Insomnia Treatments
Evolution of Insomnia Treatments BZB/BRB Z-Drugs (GABA) Melatonin Agonist Selective H1 Antagonist Prescription Growth
Slide 11: Most Existing Insomnia Agents Stimulate Sleep Via GABA
Most Existing Insomnia Agents Stimulate Sleep Via GABA GABA-acting sleep products induce sedation via non-selective suppression of CNS arousal mechanism Promote sleep but with risks of amnesia, motor un-coordination, complex sleep behaviors (sleep driving, etc.) Schedule IV controlled substances
Slide 12: Fundamentally Different MOA
Fundamentally Different MOA Histamine (H1) is one of several waking neuro- transmitters important in the arousal system SILENOR(tm) has high affinity for H1 receptors SILENOR(tm) has significant effects at night through the blockade of H1, which promotes and maintains sleep H1 blockade does not prev
Slide 13: SILENOR: Potent and Specific H1 Antagonist
1 SILENORTM: Potent and Specific H1 Antagonist Richelson (1994) 10 100 1,000 10,000 Inverse Affinity (1/Kd (nM) x 10,000) Doxepin Amitriptyline Diphenhydramine Trazodone SILENOR(tm) exhibits potent and specific H1 effects without clinically relevant binding to other receptors associated with next da
Slide 14: Differentiated Product Profile: Efficacy
Differentiated Product Profile: Efficacy In multiple clinical trials, SILENOR(tm) has demonstrated: Sleep Onset Sleep Maintenance Prevention of Early Awakenings Efficacy in Adults Elderly Chronic and transient insomniacs Improves Sleep Quality Long Term Studies - Sustained Effect
Slide 15: Phase 3 Adult Chronic Insomnia PSG Trial: Sleep Efficiency by Hour
PBO DXP 3mg DXP 6mg 0 1 0.505 0.62 0.606 2 0.783 0.901 0.914 3 0.848 0.933 0.93 4 0.861 0.909 0.932 5 0.829 0.898 0.901 6 0.807 0.894 0.93 7 0.852 0.888 0.912 8 0.745 0.878 0.884 DXP 6mg DXP 3mg PBO SILENOR(tm) Phase 3 Adult Chronic Insomnia PSG Trial Sleep Efficiency (SE) - by Hour Night 1 Hour Nig
Slide 16: Phase 3 Elderly Chronic Insomnia PSG Trial (3 months)
PBO DXP 1mg DXP 3mg Baseline Night 15 0.4 0.53 0.68 Night 29 0.43 0.58 0.71 Night 57 0.47 0.66 0.8 Night 85 0.41 0.72 0.74 SILENOR(tm) Phase 3 Elderly Chronic Insomnia PSG Trial (3mos) p=0.0008 p=0.0985 p=0.1578 p=0.0003 p=0.0211 p=0.0001 p<0.0001 P=0.0011 CGI (Patient) - Therapeutic Effect % Indica
Slide 17: Phase 3 Elderly Chronic Insomnia PSG Trial: CGI Clinician
PBO DXP 1mg DXP 3mg Baseline Night 15 0.22 0.23 0.41 Night 29 0.23 0.35 0.41 Night 57 0.26 0.4 0.5 Night 85 0.25 0.43 0.5 SILENOR(tm) Phase 3 Elderly Chronic Insomnia PSG Trial (3mos) CGI (Clinician) - Therapeutic Effect % With Moderate/Marked Improvement DXP 3mg DXP 1mg PBO
Slide 18: Phase 3 Elderly Chronic Insomnia Trial (4 week outpatient)
PBO DXP 6mg Baseline Week 1 0.35 0.45 Week 2 0.32 0.48 Week 3 0.38 0.51 Week 4 0.36 0.49 SILENOR(tm) Phase 3 Elderly Chronic Insomnia Trial (4wk outpt) Week of study p<0.0221 p=0.0564 p=0.0307 p=0.0226 DXP 6mg PBO CGI (Patient) - Therapeutic Effect % Indicating Less Time to Fall Asleep
Slide 19: Differentiated Product Profile: Safety and Tolerability
Differentiated Product Profile: Safety and Tolerability In multiple clinical trials, SILENORTM has demonstrated: Low drop out rate in clinical trials <10% AEs comparable to PBO No amnesia, hallucinations No complex sleep behaviors No next day residual effects at proposed starting doses No tolerance
Slide 20: Successfully Completed Clinical Program Supports Product Profile
ONSET ONSET MAINTENANCE MAINTENANCE DURATION DURATION PREVENT EARLY AWAKENINGS PREVENT EARLY AWAKENINGS LPS LSO WASO sWASO TST sTST WTAS SE hr 8 P2 Elderly P2 Elderly P3 Adult P3 Transient P3 Elderly 3 mo. P3 Elderly SILENOR(tm) Successfully Completed Clinical Program Supports Product Profile KEY: p
Slide 21: What Do Patients Want?
A FULL night's sleep A GOOD night's sleep To wake up without hangover or other side effects Can take nightly without fear of dependence SILENOR(tm) What do Patients Want?
Slide 22: Positioning as a Result of Phase 3
Positioning as a Result of Phase 3 First Line Therapy for Insomnia Amnesia Complex Sleep Behaviors Hormone Changes Metallic Taste Attributes SILENORTM Sonata Ambien Ambien CR Lunesta Rozerem Onset Maintenance Last 3rd of Night Long Term Studies Not Scheduled Not GABA
Slide 23: Proprietary Position - Issued Patents
Proprietary Position - Issued Patents US Patent 5,502,047-expires 2013 Method of treating chronic insomnia at low dose One relevant reference found; successful re-examination at PTO with limited impact on scope of patent protection Additional references submitted in a reissue proceeding; proceeding
Slide 24: Proprietary Position - Pending Applications
Proprietary Position - Pending Applications Multiple new applications covering key safety and efficacy data in the proposed label Method of improving PK Formulation and manufacturing processes Method of preventing early awakenings and improving sleep efficiency Method of treating insomnia without se
Slide 25: Proprietary Position - Life Cycle Management
Proprietary Position - Life Cycle Management Pending applications relating to next generation products Orally disintegrating formulations Combination drug formulations Multi-layer formulations Method of treating insomnia with ultra low dose doxepin
Slide 26: SILENOR Regulatory Status January 2008
SILENOR(tm) Regulatory Status January 2008 All pivotal clinical trials successfully completed NDA submission planned for Q1 2008 will include: Preclinical genotoxicity & reproductive tox data 26 week carcinogenicity results 2 year carc preclinical study initiated; plan to submit data as post-approva
Slide 27: Doxepin: A Long History
On the market >37years Dosed 10-50x > proposed SILENOR(tm) dosing Estimated >100M Rx's since approval Chronic usage typically at 75-150mg/day Doxepin: A Long History 10 25 50 75 300 Depression 1 6 Insomnia SILENOR(tm) 3 Doxepin
Slide 28: Changing Market Dynamics
Changing Market Dynamics Competition is moving away from launch phase: Promotional spending is decreasing Number of primary details are decreasing SILENOR(tm) has potential to be the first new product entry since 2006 Due to its highly differentiated product profile, SILENOR(tm) will generate favora
Slide 29: Accessible Market: Prescriptions per Decile
6.2 12.4 18.6 24.8 31 62 Rxs per Decile 6.2 12.4 18.6 24.8 31 62 Accessible Market Cumulative Rx's Per decile (in millions) 534,766 42,396 28,957 18,170 9,745 3,572 Cumulative # of MDs per decile
Slide 30: Commercial Planning
Commercial Planning Market preparation activities underway Publications Symposia Positioning Messaging Branding Planning activities for co-promotion to specialists Continuing discussions regarding strategic collaborations
Slide 31: Strategic Collaboration for SILENOR
Strategic Collaboration for SILENOR(tm) GOAL: Maximize shareholder value Traditional licensing with co-promotion rights Co-promotion with shared revenues and costs M&A to gain access to sales infrastructure/ products
Slide 32: Financial Highlights
Financial Highlights Cash, cash equivalents & short term investments Shares outstanding Fully diluted shares $40.8 mm 18.2 mm 21.4 mm Cash runway Cash, cash equivalents & short term investments (9/30/07) Cash runway at least through 2008
Slide 33: Somaxon Highlights
Somaxon Highlights Specialty pharmaceuticals focused on psychiatric and neurologic disorders Product candidate SILENOR(tm) for treatment of insomnia Completed four successful Phase 3 clinical trials Differentiated product profile Significant market potential 2008 Goals File NDA in Q1 Establish strat
Somaxon Pharmaceuticals — Investor Presentation (January 2008) on 6ix